Design 制药 DSGN
$10.21 +$0.54 (+5.58%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $10.21 0.00%
开盘$9.73
昨收$9.67
当日区间$9.70 – $10.34
成交量330.6K
市值$653.81M
市盈率（TTM）–
股息率–
DSGN 相关新闻
匹配 Design Therapeutics 或代码 DSGN 的头条新闻，按最新排序。
- Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22
- Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
- Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21 正面
- Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20
- RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 正面
- Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 正面
- Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 正面
- RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $14 正面
- Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $15
- Jefferies Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15
- Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $18
- RBC Capital Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $14
- Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)
- Wells Fargo Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $26
- Oppenheimer Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $18
暂无评论——快来第一个聊聊 DSGN。
登录后参与讨论。